Merck’s shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

New 100-week data from the ongoing Phase I/II study of zigakibart, an investigational anti-APRIL monoclonal antibody, ...

Respiratory syncytial virus (RSV) causes millions of childhood illnesses yearly, particularly in poorer countries. On 30 May 2025, the World Health Organisation issued its first global guidance ...

Sibeprenlimab targets a protein called A proliferation-inducing ligand (APRIL), and the drug is designed to limit the ...

A growing body of research indicates that plasma exchange therapy may slow biological aging. But do experts actually ...

Dietmar Berger, M.D., Ph.D., joined Gilead Sciences as chief medical of | Dietmar Berger became Gilead Sciences’ new chief ...

Pharmaceutical Technology serves as the connection to bio manufacturing and development, featuring regulatory updates and ...

As soon as his doctor saw it, he cut it out. Surgical excision, and sometimes additional radiation therapy, is the typical ...

A second-generation anti-CD40 therapy that inhibits B- and T-cell activity nearly eliminated multiple sclerosis activity over ...

Breast cancer study results impressed at this year’s meeting, but raised new questions. Doctors also wrestled with how best ...

New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal antibody, ...

The FDA has approved Nucala (mepolizumab) for the add-on maintenance treatment of patients with inadequately controlled eosinophilic COPD.